



SOLVAY

asking more from chemistry®

THIRD QUARTER 2016 RESULTS

*November 8
2016*

SAFE HARBOR

This presentation may contain forward-looking information. Forward-looking statements describe expectations, plans, strategies, goals, future events or intentions. The achievement of forward-looking statements contained in this presentation is subject to risks and uncertainties relating to a number of factors, including general economic factors, interest rate and foreign currency exchange rate fluctuations, changing market conditions, product competition, the nature of product development, impact of acquisitions and divestitures, restructurings, products withdrawals, regulatory approval processes, all-in scenario of R&D projects and other unusual items.

Consequently, actual results or future events may differ materially from those expressed or implied by such forward-looking statements. Should known or unknown risks or uncertainties materialize, or should our assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly update or revise any forward-looking statements

This document does not constitute an offer to sell, or the solicitation of an offer to subscribe for or buy, any securities.

The results of former Cytec are consolidated in the Group's income and cash flow statements since January 1, 2016. Comparative information for the third quarter and first nine months of 2015 is presented on an unaudited pro forma basis as if the acquisition of Cytec had taken place on January 1, 2015.

Besides IFRS accounts, Solvay also presents underlying Income Statement performance indicators to provide a more consistent and comparable indication of the Group's financial performance. The underlying performance indicators adjust IFRS figures for the non-cash Purchase Price Allocation (PPA) accounting impacts related to acquisitions, for the coupons of perpetual hybrid bonds, classified as equity under IFRS but treated as debt in the underlying statements, and for other elements that would distort the analysis of the Group's underlying performance.

The comments on the results are made on an underlying basis unless otherwise stated.

OVERVIEW

- **Transformation delivery**
- Financial highlights
- Priorities and outlook
- Annexes



SOLVAY

asking more from chemistry®

EXECUTING OUR PLAN



Q3 2016

- **Profit growth and record margin**
- **Pricing power maintained**
- **Sustained excellence efforts**
- **Acceleration of synergies**
- **Strong cash generation**

Delivering on priorities



THIRD QUARTER RESULTS

RECORD MARGIN & SOLID CASH GENERATION

EBITDA
6% ↗

- Pricing power ↗
 - Sustained for 11 quarters
- Lower fixed costs
 - Benefiting from synergies and excellence
- Volume ↘
 - Soft market demand in smart devices, oil & gas & other specific markets
 - Offsetting growth elsewhere

Record EBITDA
margin at 23%

Free Cash Flow ^[1]
14% ↗

- Resulting from
 - Higher EBITDA
 - Lower CapEx
 - Working capital discipline
- Underlying net debt reduced to € 6.5 bn
 - Leverage 2.9x → 2.7x

Higher cash
conversion at 64%

OVERVIEW

- Transformation delivery
- **Financial highlights**
- Priorities and outlook
- Annexes



SOLVAY

asking more from chemistry®

SOLID RESULTS

FINANCIAL HIGHLIGHTS Q3 2016

€ 2.9 bn

Net Sales

-8%

yoy

- ↘ **Volume** down across operating segments in specific markets
- ↘ **Prices** down linked to pass-through of lower raw material prices and pressure in oil & gas and Latin American markets

€ 664 m

Underlying EBITDA

+6%

yoy

- ↗ **Pricing power** supported by operational excellence
- ↗ **Fixed costs** reduced through synergies, and operational excellence, offsetting inflation and new capacity costs

€ 247 m

Underlying net income

Group share

€ 214 m

In Q3 2015

- ↗ **EBIT** up
- Higher **net financial charges** offset by lower **taxes**

€ 280 m

Free cash flow

Continuing operations

€ 245 m


in Q3 2015

- ↗ **EBITDA** up
- ↗ Lower **capex** in line with year guidance
- ↗ **Working capital** discipline

SALES DOWN WITH SOFTER DEMAND IN CERTAIN MARKETS

Net sales

in € m



➤ Volumes lower

- Slower demand ramp-up for smart devices
- Soft demand in composites
- Contraction in oil & gas market
- Temporary production stops at Peroxides and chlorovinyls
- Offsetting growth in other businesses, e.g. automotive


➤ Lower prices

- Partial pass-through of lower raw material costs in deflationary market
- Pressure in Latin American and O&G markets

RECORD EBITDA MARGIN UNDERPINNED BY EXCELLENCE AND SYNERGIES

Underlying EBITDA

in € m




➤ **Pricing power**
in all segments, except Advanced Formulations, supported by operational excellence

➤ **Fixed costs**
down on synergies, while excellence offset inflation and new capacity costs

➤ **Conversion forex**
mainly from depreciation Venezuelan bolivar

RESILIENCE THROUGH MULTI-SPECIALTY PORTFOLIO

MARGINS FLAT TO IMPROVED OVER SEGMENTS



UNDERLYING NET INCOME REFLECTING HIGHER OPERATING PROFIT

Underlying P&L

in € m

	Q3 2016	Q3 2015 pro forma	% yoy
Net sales	2,921	3,162	(8)%
EBITDA	664	625	6%
<i>EBITDA margin</i>	<i>23%</i>	<i>20%</i>	<i>3pp</i>
Depreciation & amortization	(198)	(196)	(1)%
EBIT	466	429	9%
Net financial charges	(119)	(109)	(9)%
Income taxes	(86)	(95)	9%
<i>Tax rate (ytd)</i>	<i>28%</i>	<i>31%</i>	<i>(3)pp</i>
Non-controlling interests	(14)	(13)	(11)%
Net income, Solvay share	247	214	16%
PPA impact	(72)	(71)	
Portfolio management	(20)	(16)	
Remediation & litigation	(10)	(9)	
(Financial adjustments)	37	38	
(Tax adjustments)	53	47	
Discontinued operations	(56)	(4)	
(Other adjustments)	(4)	(36)	
Net income, Solvay share, IFRS	176	163	8%

Underlying net income (Solvay share) up 16%

- ↘ Net financial charges up due to forex impact on currency swaps
- ↗ Underlying tax rate at 28% ytd vs 31% ytd in 2015, due to change in geographical mix

IFRS net income (Solvay share) up 8%


- ↘ Discontinued operations reflecting fair value adjustment on anticipated Indupa sale

66% CASH CONVERSION YEAR TO DATE DRIVEN BY HIGHER EBITDA AND LOWER CAPEX

Cash conversion ^[1]

$\frac{\text{EBITDA} - \text{capex}}{\text{EBITDA}}$

Capex
Continuing
operations
in € m



→ **2016**

**Growth capex at >50% of total
~2/3rd in Advanced Materials**

- Aerospace resins line in Germany
- Expansion of Adhesives for aerospace in the U.K.
- PEEK plant in U.S.
- Fluoropolymer plant in China, phase 2

**Supplemented by
maintenance capex excellence**


Profit growth
Improved cash conversion

Sustainable improvement
in free cash flow

NET DEBT REDUCED WITH FOCUS ON CASH SUPPLEMENTED BY PORTFOLIO

Underlying net debt^[1] evolution

in € m



Free cash flow of € 280 m, up 14%

- Profit growth
- Lower capex
- Working capital discipline maintained

M&A inflow reducing net debt

- Accelerated exit payment on Inovyn
- Other M&A outflows including Primester, ...

Financial payments seasonally lower in Q3


- ➔ No dividends to Solvay or minorities
- ➔ Accruals included in "Other changes in net debt"

EFFECTIVE TREASURY MANAGEMENT LEADING TO REDUCED COST OF DEBT

Underlying debt^[1] evolution

in € bn

- EUR perpetual hybrid bonds
- USD bonds
- EUR bonds [2]
- Other debt
- Cash



Underlying

Net debt^[1]

Leverage^[3]

31/12/2015

€ 6.6 bn

2.8x

30/09/2016

€ 6.5 bn

2.7x



INVESTMENT GRADE

OVERVIEW

- Transformation delivery
- Financial highlights
- **Priorities and outlook**
- Annexes



SOLVAY

asking more from chemistry®

OUTLOOK FOR FY 2016 CONFIRMED



**EBITDA
to grow
approximately 7% - 8%**

**Free cash flow
to exceed € 700 m**

OUR COMMITMENT



Exceed expectations on synergies

Excellence & portfolio optimization continuing

Reinforced focus on cash generation

Attractive returns for shareholders



INVESTOR RELATIONS CONTACTS



Kimberly Stewart

+32 2 264 3694

kimberly.stewart@solvay.com



Jodi Allen

+1 (973) 357 3283

jodi.allen@solvay.com



Geoffroy Raskin

+32 2 264 1540

geoffroy.raskin@solvay.com



Bisser Alexandrov

+32 2 264 3687

bisser.alexandrov@solvay.com



NEXT EVENTS

**January 18
2017**

Interim dividend
payment

**February 24
2017**

Q4 & FY 2016
results

**May 3
2017**

Q1 2017
results

**May 9
2017**

Annual general
meeting

**August 1
2017**

Q2 & H1 2017
results

ANNEXES

- **Additional Q3 2016 financial data**
- Forex sensitivity & other financial considerations for 2016
- Solvay general information




SOLVAY

asking more from chemistry®


ADVANCED MATERIALS Q3 2016

HEADWINDS SMART DEVICES & COMPOSITES OFFSETTING OTHER MARKET GROWTH

Net sales (in € m)



EBITDA (in € m)



Specialty Polymers' sales slightly down

- Double-digit growth in batteries, healthcare, and consumer goods markets offset by smart devices.
- Smart devices sales improved sequentially but not against tough Q3 2015 comparable

Composite Materials facing soft demand

- Growth new aircraft programs not yet offsetting demand declines in wide-body civil aircrafts, business jets & rotorcraft
- Industrial composites sales lower

Special Chem strong volumes

- Growth from automotive catalysts continues
- Growth in high-purity H₂O₂ for use in semiconductor industry
- Negative scope effect from sale of PCC business in 2015



Silica intrinsically stable

- Volume growth in tire market and other niche segments offset by unfavorable mix
- Forex impact from devaluation of Venezuelan bolivar

ADVANCED FORMULATIONS Q3 2016


OIL & GAS NOT YET OFFSET BY OTHER MARKET GROWTH

Net sales (in € m)



■ Novecare
■ Technology Solutions
■ Aroma Performance

EBITDA (in € m)



Oil & gas continued to weigh on **Novecare**

- Sales down (14)% yoy due to oil & gas, but market stabilizing sequentially
- Growth in other markets including Agro and industrial applications partly offset oil & gas declines
- Operational excellence measures and synergies helped sustain margins

Modest sales growth in **Technology Solutions** despite mining industry challenges

- Growth in phosphorous and phosphine chemicals
- Lower Cu & Al prices driving curtailments at existing mines; new mine projects are delayed



Aroma Performance continues to face price pressure

- Volume growth in vanillin formulations
- Competitive price pressure remains

PERFORMANCE CHEMICALS Q3 2016


EBITDA GROWTH ATTRIBUTABLE TO SODA ASH & DERIVATIVES

Net sales (in € m)



■ Soda Ash & Derivatives ■ Peroxides
■ Acetow ■ Coatis

EBITDA (in € m)



Soda Ash & Derivatives driven by excellence

- Slightly lower volumes in Europe & seaborne markets
- Double-digit volume growth in bicarbonate as result of Thailand plant ramp up
- Strong excellence delivery

Peroxides sales down on lower production rates

- Impact from temporary shutdown of HPPO facilities
- Growth in traditional wood pulp & paper market offset by reduced sales in fish-farming

Acetow business stable

- Sustained recovery in market continues (with the exception of China)
- Volumes essentially flat versus prior year quarter



Coatis remains challenged

- Conditions in Latin America affecting volumes and prices


FUNCTIONAL POLYMERS Q3 2016

EXCELLENCE-DRIVEN PROFIT GROWTH

Net sales (in € m)



EBITDA (in € m)



Polyamide growth driven by volume and excellence

- Demand satisfactory with volume increases offset by price
- Significant improvement in EBITDA as a result of operational excellence programs


Chlorovinyls largely stable

- Solid contribution from RusVinyl JV (Russian operations), operating at close to full capacity
- Challenges with production in Thai operations as a result of electricity outage

CORPORATE & BUSINESS SERVICES Q3 2016

BENEFITING FROM COST DISCIPLINE

EBITDA (in € m)



<i>in € m</i>	Q3 2015 pro forma	Q3 2016	
Energy Services	(8)	5	
of which one-offs	(7)	-	CER write-off
excluding one-offs	(1)	5	
Other C&BS	(63)	(39)	
Corporate & Business Services	(71)	(34)	
of which one-offs	(7)	-	CER write-off
excluding one-offs	(64)	(34)	

Energy Services well up

- Improved business conditions
- Restructuring in renewable energy assets
- Compares with € (7) m write off for Carbon Emission Rights in Q3 2015


Significant cost reduction in Other Corporate & Business Services

- Synergy benefits
- Delivery on excellence programs
- Cost phasing effects

WORKING CAPITAL MANAGEMENT COMPENSATES FOR HIGHER NEEDS OF SPECIALTY BUSINESSES

Net working capital ^[1]

% of total sales



→ **Q1 & Q2 2016 inflated** by receivable on Inovyn exit price


→ **Working capital management efforts** offset higher working capital needs of increasing share of specialty businesses in portfolio

- Higher growth profile
- Cytec acquisition

Committed to further optimization

DEBT PROFILE

BALANCED MATURITIES ALLOWING FLEXIBILITY




Major debt ^[1]

	31/12/2015			30/09/2016		
	Face value	Average duration	Average cost	Face value	Average maturity	Average cost
EUR bonds ^[2]	3,550	4.1	2.88%	2,750	4.5	1.97%
EUR perpetual hybrid bonds ^[3]	2,200	6.1	5.07%	2,200	5.3	5.07%
USD bonds	2,142 ^[3]	7.5	4.03%	2,090 ^[4]	6.7	4.03%
Total major debt	7,892	5.6	3.80%	7,040	5.4	3.55%
	in € m	in years		in € m	in years	

NET PENSION LIABILITIES ^[1] UP ON LOWER DISCOUNT RATES

Pensions (30/09/2016)

in € bn



Net pension liabilities increase by € 0.2 bn

- Pension liabilities up to € (6.3) bn following discount rates drop
- Pension assets largely stable at € 3.0 bn


Cash contribution of € (46) m in Q3

- vs € (43) m in Q3 2015 excluding Cytec
- YTD outflow of € (139) m

Net pension liabilities

(30/06/2016)

in € bn



All presented figures are for continuing operations only

Discount rate evolution ^[2]

Currency	30/09/2016	30/06/2016	Change
EUR	1.00%	1.25%	(0.25) pp
GBP	2.25%	2.75%	(0.50) pp
USD	3.50%	3.75%	(0.25) pp
Average	2.09%	2.40%	(0.31) pp

ANNEXES

- Additional Q3 2016 financial data
- **Forex sensitivity & other financial considerations for 2016**
- Solvay general information



SOLVAY

asking more from chemistry®

UNDERLYING EBIT(DA) CONSIDERATIONS FOR 2016

Scope effects

- Acquisitions in 2015
 - Cytec full consolidation as of January 1, 2016
Pro forma 2015 restated for acquisition
 - Small acquisition in 2015: EPIC
- Divestments in 2015
 - Refrigerants (Special Chem, Advanced Materials)
in May 2015: net sales of ~€ 50 m in 2014
 - PCC (Special Chem, Advanced Materials)
in November 2015: net sales of ~€ 60 m in 2014

Depreciation & amortization

- Underlying D&A of ~€ (800) m
 - Excludes PPA amortization
- PPA amortization of ~€ (370) m
 - Includes PPA impacts from Rhodia, Cytec and other smaller acquisitions (e.g. Chemlogics, Ryton)

Forex sensitivity

- Immediate impact on conversion exposure
- Deferred transactional impact due to hedging
(6-12 month rolling basis)
- Mainly linked to USD
 - Sensitivity in 2016:
~ € 120 m REBITDA per (0.10) \$/€
 - ~60% conversion, ~40% transactional
- Other forex exposures
 - JPY, CNY, THB, BRL, KRW, RUB
- Total conversion impact on underlying EBITDA
of € (39) m in 1st 9M 2016.
- Evolution of main currencies Solvay is exposed to:

Average / €	USD	JPY	GBP	RUB	BRL	CAD	CNY	KRW	THB
9M 2016	1.12	121	0.80	76.18	3.96	1.47	7.35	1296	39.33
9M 2015	1.11	135	0.73	66.60	3.53	1.40	6.96	1253	37.62
YoY change vs €	0%	11%	-9%	-13%	-11%	-5%	-5%	-3%	-4%

UNDERLYING FINANCIAL & TAX & CASH CONSIDERATIONS FOR 2016

Cost of borrowings

Total underlying financial charges expected at ~€ (370) m (incl. perpetual hybrid bonds)

- Financial charges from major senior debt (excl. perpetual hybrid bonds)
 - 2016 charges expected at ~€ (150) m
 - At end Q3'16, average cost 2016 is 2.9% (2015: 5.2%) vs 3.3% before reimbursement of EIB loan of € 300 m reimbursed in January and € 500 m hybrid bond in June 2016.
- Coupons from perpetual hybrid bonds (considered as dividend & equity under IFRS)
 - 2016 cash out of € (84) m: Q2 € (57) m / Q4 € (27) m
 - From 2017 onwards € (112) m: Q2 € (84) m / Q4 € (27) m
 - Average cost : 5.1%
- Other elements ~€ (100-120) m
 - Currency swaps & other debt in consolidated subsidiaries
 - Financial charges RusVinyl^[2]: ~€ (25) m

Discounting of pensions and HSE

- P&L: ~€ (110) m ($\frac{3}{4}$ - pensions, $\frac{1}{4}$ - HSE)
- Sensitivity to change in discount rates^[1]: ~€ (370) m / 50bp
 - Pensions (in OCI):
€zone ~€ (150) m; UK ~€ (140) m; USA ~€ (80)m
 - HSE (in P&L): ~€ (5) m

Tax rate

Underlying tax rate (adjusted for PPA and other factors) expected stable in the low ~30s

Cash flow elements

- Cash expenses for pensions expected in € (180) m - € (200) m range
- Capital expenditure expected at ~€ (950) m

OTHER CONSIDERATIONS FOR 2016

Discontinued operations

- Indupa chlorovinyls business in Latin America
 - Agreement reached on 02/05/2016 to sell to Brazilian chemical group Unipar Carbocloro for EV of US\$ 202 m, subject to closing conditions
 - ~€ (50) m CTA to be recycled through P&L at exit

Inovyn JV

- Beginning of July 2016, Solvay has completed the divestment of its shareholding in Inovyn, bringing to an end its chlorovinyls joint venture with Ineos.
- Solvay received exit cash proceeds amounting to €335 million.
- Solvay to pay price adjustment of ~€ (80) m in 2017.

Underlying adjustments to IFRS figures

- To improve comparability of results over periods
- Exclusion of
 - Amortization of PPA and inventory step-up from acquisitions
 - Impact of portfolio management and reassessments
 - Legacy remediation and major litigations
 - Exceptional financial elements, such as hyperinflation
 - Impact of change in rates on discounting charges
 - Tax impacts related to previous periods
 - Valuation impacts of discontinued operations
- Reclassification of
 - Coupons of perpetual hybrid bonds as net financial charges (considered as equity under IFRS)
 - Financial charges RusVinyl as net financial charges (only realized gains/losses)
- Impact of the above on tax and share of non-controlling interests

ANNEXES

- Additional Q3 2016 financial data
- Forex sensitivity & other financial considerations for 2016
- **Solvay general information**



SOLVAY

asking more from chemistry®

OUR VISION CREATING A FUTURE WITH *MORE* POTENTIAL



**Building
a new model of
sustainable chemistry
to help answer some of
society's challenges**


**Leading to long-term
value growth
for our stakeholders**




EXECUTING OUR STRATEGY IN-DEPTH TRANSFORMATION



UPGRADING OUR BUSINESS PROFILE ACTIVE PORTFOLIO MANAGEMENT



MORE




[1] Agreement to divest reached, awaiting regulatory approvals

WE ARE MORE GLOBAL

GEOGRAPHIES

- Europe
- Asia & RoW
- Latin America
- North America




2010
€ 6 bn
let sale

2015 ⁽¹⁾
€12 bn
let sale

MARKETS

- Automotive & aerospace
- Resources & environment
- Electrical & electronics
- Agro, feed & food
- Consumer goods & healthcare
- Building & construction
- Industrial applications




DIVERSIFIED

(1) Pro forma, as if Cytec consolidated in 2015

WE ARE MORE SPECIALTY



Net sales
pro forma



- Advanced Materials
- Performance Chemicals
- Advanced Formulations
- Functional Polymers


Diversified chemicals

Innovation-driven
Specialty

RESULTING IN VALUE DELIVERY IMPROVED VS BENCHMARKS


PROFIT

EBITDA margin




CASH

Cash conversion



RETURNS


HOLT CFROI^[2]



[1] Akzo Nobel, Arkema, BASF, Clariant, DSM, Evonik, Lanxess (metrics as could be deducted from reporting)

[2] HOLT CFROI is a proprietary cash flow return on investment metric of Credit Suisse calculated as an IRR taking into account i) the cash flow generated by a company in the past and prospectively and ii) the amount and estimated lifespan of its operating assets. The metric does not include goodwill and is expressed in real terms (i.e. real returns and not nominal ones).

ALIGNED BUSINESS SEGMENTS STRATEGICALLY COHERENT TO DRIVE RESULTS



Market positions:

- Global market position in main markets addressed
- Regional market position in main markets addressed

2015 pro forma GROUP

Net sales	€ 12,378 m
REBITDA	€ 2,336 m
margin	19%
CFROI	6.1%

GROWTH ENGINES

ADVANCED MATERIALS

High performance materials, providing solutions for sustainable mobility: **light-weighting**, CO₂ and energy efficiency

Specialty Polymers **#1**

Composite Materials **#2**

Special Chem **#1**

Silica **#1**

ADVANCED FORMULATIONS

Customized specialty formulations in **surface chemistry**, optimizing efficiency, minimizing environmental impact

Novecare **#1**

Technology Solutions **#1**

Aroma Performance **#1**

RESILIENT CASH CONTRIBUTOR

PERFORMANCE CHEMICALS

Leading positions in chemical intermediates, through scale and technology

Soda Ash & Derivatives **#1**

Peroxides **#1**

Acetow **#4**

Coatis **#1**

FUNCTIONAL POLYMERS

Leading regional positions in functional polymers, with focus on excellence

Polyamide **#3**

Chlorovinyls **#2**

MORE VALUE THAT STANDS THE TEST OF TIME

3 years
2016 - 2018

PLANET

GHG intensity
kg CO₂ eq. emissions / € EBITDA
Sustainable
Solutions
% Group sales

-20%
reduction to 5.8
7%
increase to 40%

PEOPLE

Accident rate
Acc. with medical treatment / m working hours
Employee engagement
index

-10%
reduction to 0.69
Maintain
at 75%

SOCIETY

Societal actions
% employees involved

5%
increase to 25%

At constant forex & scope

3 years
2016 - 2018

PROFIT

EBITDA^[1] growth

**Mid-to-high
single digit**
% yoy

CASH

Free cash flow
Cash conversion

> € 2.4 bn
cumulative
> 60%
each year

RETURNS

CFROI

50 - 100 bp
increase

[1] underlying EBITDA

MID-TO-HIGH SINGLE DIGIT PROFIT GROWTH

OPERATIONAL EXCELLENCE

→ € 450 m by 2018

CYTEC SYNERGIES

→ € 150 m by 2018


BUSINESS GROWTH

Supported by

- Innovation
- Commercial excellence
- New capacity
- Debottlenecking

UNDERLYING EBITDA

(in € m)



At constant forex & scope,
based on slow to moderate markets growth

MORE CASH

FCF > € 2.4 bn OVER 3 YEARS TO 2018

→ **Underlying EBITDA**
mid-to-high single digit growth

→ **Capex intensity**
to reduce


→ **Net working capital intensity**
stable

→ **Pensions & other provisions**
net cash-out ~ € 360 m ^[1]

→ **Tax rate**
at ~30%

FREE CASH FLOW

(in € m)




At constant forex & scope

[1] Primarily and on average

- ~ 50% annual cash-outs for pensions & other personnel benefits (excl. service costs in EBITDA)
- ~ 50% of portfolio management and reassessments (including restructuring) and legacy HSE remediation and major litigations

REDUCING GREENHOUSE GAS EMISSIONS TO REDUCE CLIMATE CHANGE IMPACT





KEY LEVERS

- **Portfolio**
- **SolWatt excellence**
 - Energy efficiency
 - Energy mix
- **Capex challenge**
 - Internal carbon price
€ 25 / tonne CO₂

BUILDING AN UPGRADED PORTFOLIO WITH MORE SUSTAINABLE SOLUTIONS

SUSTAINABLE PORTFOLIO MANAGEMENT

(in % of net sales)



KEY LEVERS

- Portfolio
- Capex
- R&I priorities

MOVING TOWARDS MULTI-SPECIALTY



ADVANCED MATERIALS

Providing solutions
for sustainable mobility,
lightweighting,
CO₂ and energy
efficiency



ADVANCED FORMULATIONS

Customized specialty
formulations in surface
chemistry and liquid
behaviour, maximizing
yield & efficiency,
minimizing eco impact



PERFORMANCE CHEMICALS & FUNCTIONAL POLYMERS

Leading positions
in chemical intermediates
through scale and
technology, developing
innovative application and
industrial innovation for
optimized costs



MORE Growth, Returns & Resilience

DRIVING SUSTAINABLE MOBILITY ON THE ROAD

New Industry Paradigm:

- Sustainability
- Shared Mobility
- Connectivity

- Regulations driving CO₂ emissions reductions
- Car sharing services and self-driving cars
- Safety: Zero casualties

SOLVAY ENABLING SOLUTIONS



Lightweighting



Powertrain Efficiency



Electrification

DRIVING SUSTAINABLE MOBILITY IN THE AIR

Fundamental Value of Composites

Lightweighting

Aerodynamics

Fatigue life

Corrosion resistance

Lean manufacturing
lower part cost


Increased
passenger comfort

Life-of-program
maintenance costs



SOLVAY
ENABLING SOLUTIONS

DRIVING SUSTAINABLE MOBILITY BEYOND TODAY



ARTISANAL

Composites Evolution

INDUSTRIALIZATION



Solvay's complementary technologies and competencies enable us to meet future industrialization challenges!

PLANET

PROFIT

PEOPLE

CASH

SOCIETY

RETURNS

MORE
Sustainable
VALUE

Solvay's ADR program

Convenience of investing in American Depositary Receipts (ADRs) through a sponsored Level 1 program

ADR Symbol	SOLVY
Platform	OTC
CUSIP	834437303
DR ISIN	US834437305
Underlying ISIN	BE0003470755
SEDOL	BD87R68
Depository bank	Citi
ADR ratio	1 ORD : 10 ADR

Benefits of ADRs:

- Clear and settle according to US standards
- Convenience of stock quotes and dividend payments in US dollars
- Purchase in the same way as other US stocks via a US broker
- Cost effective means of building an international portfolio

For questions about creating Solvay ADRs, please contact Citi:

New York

Michael O'Leary

michael.oleary@citi.com

Tel: +1 212 723 4483

London

Mike Woods

michael.woods@citi.com

Tel: +44 20 7500 2030



SOLVAY

asking more from chemistry®